<DOC>
	<DOCNO>NCT02633787</DOCNO>
	<brief_summary>The aim study provide information persistence bactericidal antibodies follow Menactra booster vaccination study MTA77 ( NCT01442675 ) . Objective : - To evaluate persistence antibody response ( determine serum bactericidal assay use human complement ( SBA-HC ) ) approximately 4 year administration booster dose Menactra vaccine trial MTA77</brief_summary>
	<brief_title>Persistence Bactericidal Antibodies Adults Who Received Booster Dose Menactra® Approximately 4 Years Earlier</brief_title>
	<detailed_description>All eligible subject provide 1 blood sample Visit 1 . The duration subject 's participation trial duration 1 visit ( enrollment blood draw )</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Aged ≥ 18 year day inclusion Received booster dose Menactra vaccine trial MTA77 Informed consent form sign date Able attend schedule visit comply trial procedure . Participation time trial enrollment ( 4 week precede trial enrollment ) another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt meningococcal vaccine , include serogroup B meningococcal vaccine , receipt booster dose Menactra vaccine administer trial MTA77 Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History meningococcal infection , confirm either clinically , serologically , microbiologically Bleeding disorder , thrombocytopenia , receipt anticoagulant contraindicate venipuncture discretion Investigator Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction Any illness , opinion Investigator , might interfere trial conduct trial result Receipt oral injectable antibiotic therapy within 72 hour prior blood draw . ( A prospective subject include trial 72 hour pass . ) Identified Investigator employee Investigator trial center direct involvement propose trial , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>Meningococcal Infections</keyword>
	<keyword>Menactra®</keyword>
</DOC>